Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (The Novo Study)

Journal of Neurology

Volumn 257, Issue 9, 2010, Pages 1500-1507

  Fernandez O ^a   Fernandez V ^a   Arbizu, T ^b   Izquierdo, G ^c   Bosca, I ^d   Arroyo, R ^e   Garcia Merino J A ^f   De Ramon E ^a   Pinel, Lucía Romero ^g   Gubieras, Laura ^g   Echenique, Yersinia Tordecilla ^g   Fernández, Oscar ^g   Torres, Ana Alonso ^g   Puras, Manuel Bartolomé ^g   de las Heras, Virginia ^g   Martín, Carmen ^g   Fernández, Ciara García ^g   Dib, Wadih Bowakin ^g   Montalbán, Xavier ^g   Perkal, Héctor D ^g   Fernández, Carmen ^g   Martinez, Jesús Martín ^g   Gómez, Manuel Arias ^g   Montero, Ma Rosa García ^g   Cermeño, José Carlos Alvarez ^g   more..

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^g NONE

Author keywords

Diagnosis; Early treatment; Multiple sclerosis

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL PRACTICE; CONSULTATION; CONTROLLED STUDY; DIAGNOSIS; DIAGNOSTIC TEST; EVOKED RESPONSE; FEMALE; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT REFERRAL; PHYSICIAN; PRIORITY JOURNAL; SCHOOL CHILD; SPAIN;

EID: 77957373324     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-010-5560-1     Document Type: Article

References (57)

1. Álvarez-Cermeño JC, Arroyo R, Arbizu T, de Andrés C, Fernández O, García-Merino A, Hernández M, Izquierdo G, Montalbán X, Polman CH (2003) Guía oficial para el diagnóstico y tratamiento de la esclerosis múltiple. Barcelona
2. A Boster G Edan E Frohman A Javed O Stuve A Tselis H Weiner B Weinstock-Guttman O Khan 2008 Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician Lancet Neurol 7 173 183 10.1016/S1474-4422(08)70020-6 1:CAS:528:DC%2BD1cXis1WmsLk%3D 18207115
3. PA Brex O Ciccarelli JI O'Riordan M Sailer AJ Thompson DH Miller 2002 A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158 164 10.1056/NEJMoa011341 11796849 (Pubitemid 34438881)
4. AJ Coles DA Compston KW Selmaj SL Lake S Moran DH Margolin K Norris PK Tandon 2008 Alemtuzumab vs. interferon beta-1a in early multiple sclerosis N Engl J Med 359 1786 1801 10.1056/NEJMoa0802670 18946064
5. G Comi 2009 Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta Clin Ther 31 1142 1157 10.1016/j.clinthera.2009. 06.007 19695384
6. G Comi L Leocani S Medaglini T Locatelli V Martinelli G Santuccio P Rossi 1999 Evoked potentials in diagnosis and monitoring of multiple sclerosis Electroencephalogr Clin Neurophysiol Suppl 49 13 18 1:STN:280: DC%2BD3c%2FgtlaksA%3D%3D 10533079
7. G Comi V Martinelli M Rodegher L Moiola O Bajenaru A Carra I Elovaara F Fazekas H Hartung J Hillert J King S Komoly C Lubetzki X Montalban K Myhr M Ravnborg P Rieckmann D Wynn C Young M Filippi 2009 Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial Lancet 374 9700 1503 1511 10.1016/S0140-6736(09)61259-9 1:CAS:528:DC%2BD1MXhtlCmt7zN 19815268
8. A Compston A Coles 2008 Multiple sclerosis Lancet 372 1502 1517 10.1016/S0140-6736(08)61620-7 1:CAS:528:DC%2BD1cXht12gtLvN 18970977
9. C Confavreux S Vukusic 2006 Natural history of multiple sclerosis: a unifying concept Brain 129 606 616 10.1093/brain/awl007 16415308 (Pubitemid 43278223)
10. C Confavreux S Vukusic P Adeleine 2003 Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process Brain 126 770 782 10.1093/brain/awg081 12615637 (Pubitemid 36372978)
11. PK Coyle 2008 Early treatment of multiple sclerosis to prevent neurologic damage Neurology 71 S3 S7 10.1212/WNL.0b013e31818f3d6f 1:CAS:528: DC%2BD1cXhsVOgsLnM 19064872
12. DM Dawson 2008 Benign multiple sclerosis: some recent ideas Curr Neurol Neurosci Rep 8 1 4 10.1007/s11910-008-0001-6 18367032 (Pubitemid 351166409)
13. RG Edwards JH Barlow AP Turner 2008 Experiences of diagnosis and treatment among people with multiple sclerosis J Eval Clin Pract 14 460 464 10.1111/j.1365-2753.2007.00902.x 18373567 (Pubitemid 351643263)
14. M Filippi M Rovaris M Inglese F Barkhof N De Stefano S Smith G Comi 2004 Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial Lancet 364 1489 1496 10.1016/S0140-6736(04)17271-1 1:CAS:528:DC%2BD2cXovVKrtrw%3D 15500893 (Pubitemid 39410414)
15. NC Fox R Jenkins SM Leary VL Stevenson NA Losseff WR Crum RJ Harvey MN Rossor DH Miller AJ Thompson 2000 Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI Neurology 54 807 812 1:STN:280: DC%2BD3c7lt1yhtA%3D%3D 10690967
16. D Franciotta M Salvetti F Lolli B Serafini F Aloisi 2008 B cells and multiple sclerosis Lancet Neurol 7 852 858 10.1016/S1474-4422(08)70192-3 1:CAS:528:DC%2BD1cXhtFWmsLrL 18703007
17. MS Freedman LD Blumhardt B Brochet G Comi JH Noseworthy M Sandberg-Wollheim SP Soelberg 2002 International consensus statement on the use of disease-modifying agents in multiple sclerosis Multiple Scler 8 19 23 1:STN:280:DC%2BD383gtlyhtw%3D%3D
18. MS Freedman DG Patry F Grand'Maison ML Myles DW Paty DH Selchen 2004 Treatment optimization in multiple sclerosis Can J Neurol Sci 31 157 168 15198439
19. E Frohman T Phillips K Kokel PJ Van S O'Leary S Gross K Hawker M Racke 2002 Disease-modifying therapy in multiple sclerosis: strategies for optimizing management Neurologist 8 227 236 10.1097/00127893-200207000-00003 12803682
20. DS Goodin D Bates 2009 Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode Multiple Scler 15 10 1175 1182 10.1177/1352458509107007 1:CAS:528:DC%2BD1MXhsVOgsbfJ
21. E Idiman S Ozakbas Y Dogan G Kosehasanogullari 2009 The significance of oligoclonal bands in multiple sclerosis: relevance of demographic and clinical features, and immunogenetic backgrounds J Neuroimmunol 212 121 124 10.1016/j.jneuroim.2009.04.014 1:CAS:528:DC%2BD1MXosVyktLs%3D 19457560
22. LD Jacobs RW Beck JH Simon RP Kinkel CM Brownscheidle TJ Murray NA Simonian PJ Slasor AW Sandrock 2000 Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS study group N Engl J Med 343 898 904 10.1056/NEJM200009283431301 1:CAS:528: DC%2BD3cXntFOkt7k%3D 11006365
23. B Jasperse A Minneboo V de Groot NF Kalkers PE van Helden BM Uitdehaag F Barkhof CH Polman 2007 Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis Arch Neurol 64 190 194 10.1001/archneur.64.2.190 17296834
24. OH Kantarci BG Weinshenker 2005 Natural history of multiple sclerosis Neurol Clin 23 17 38 10.1016/j.ncl.2004.10.002 15661086 v (Pubitemid 40126913)
25. L Kappos MS Freedman CH Polman G Edan HP Hartung DH Miller X Montalban F Barkhof EW Radu L Bauer S Dahms V Lanius C Pohl R Sandbrink 2007 Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study Lancet 370 389 397 10.1016/S0140-6736(07)61194-5 1:CAS:528:DC%2BD2sXosFKktLc%3D 17679016 (Pubitemid 47189673)
26. JF Kurtzke 1983 Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1444 1452 1:STN:280:DyaL2c%2FktValsQ%3D%3D 6685237
27. A Langer-Gould RA Popat SM Huang K Cobb P Fontoura MK Gould LM Nelson 2006 Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review Arch Neurol 63 1686 1691 10.1001/archneur.63.12.1686 17172607 (Pubitemid 44925075)
28. H Lassmann W Bruck C Lucchinetti 2001 Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy Trends Mol Med 7 115 121 10.1016/S1471-4914(00)01909-2 1:CAS:528:DC%2BD3MXivVGls7Y%3D 11286782 (Pubitemid 32201673)
29. H Lassmann CF Lucchinetti 2008 Cortical demyelination in CNS inflammatory demyelinating diseases Neurology 70 332 333 10.1212/01.wnl.0000298724.89870.d1 18227414 (Pubitemid 351653393)
30. C Lebrun C Bensa M Debouverie S Wiertlevski D Brassat J De Seze L Rumbach J Pelletier P Labauge B Brochet A Tourbah P Clavelou 2009 Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients Arch Neurol 66 841 846 10.1001/archneurol. 2009.119 19597085
31. L Leocani G Comi 2000 Neurophysiological investigations in multiple sclerosis Curr Opin Neurol 13 255 261 10.1097/00019052-200006000-00004 1:STN:280:DC%2BD3cvptlWqtw%3D%3D 10871248 (Pubitemid 30406531)
32. L Leocani M Rovaris FM Boneschi S Medaglini P Rossi V Martinelli S Amadio G Comi 2006 Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study J Neurol Neurosurg Psychiatry 77 1030 1035 10.1136/jnnp.2005.086280 1:STN:280:DC%2BD28vptVKluw%3D%3D 16735397 (Pubitemid 44338523)
33. H Link YM Huang 2006 Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness J Neuroimmunol 180 17 28 10.1016/j.jneuroim.2006.07.006 1:CAS:528: DC%2BD28Xht1SmsL%2FF 16945427 (Pubitemid 44692326)
34. C Lucchinetti 2008 Pathological heterogeneity of idiopathic central nervous system inflammatory demyelinating disorders Curr Top Microbiol Immunol 318 19 43 10.1007/978-3-540-73677-6-2 1:CAS:528:DC%2BD1cXhs12rsL0%3D 18219813
35. C Lucchinetti W Bruck J Parisi B Scheithauer M Rodriguez H Lassmann 2000 Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination Ann Neurol 47 707 717 10.1002/1531-8249(200006)47:6<707:: AID-ANA3>3.0.CO;2-Q 1:STN:280:DC%2BD3czgvFektA%3D%3D 10852536 (Pubitemid 30390191)
36. J Mandrioli P Sola R Bedin M Gambini E Merelli 2008 A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease J Neurol 255 1023 1031 10.1007/s00415-008-0827-5 1:CAS:528:DC%2BD1cXpvFyhsL0%3D 18535872
37. RA Marrie G Cutter T Tyry O Hadjimichael D Campagnolo T Vollmer 2005 Changes in the ascertainment of multiple sclerosis Neurology 65 1066 1070 10.1212/01.wnl.0000178891.20579.64 1:STN:280:DC%2BD2MrktFCntA%3D%3D 16217060 (Pubitemid 41429632)
38. WI McDonald A Compston G Edan D Goodkin HP Hartung FD Lublin HF McFarland DW Paty CH Polman SC Reingold M Sandberg-Wollheim W Sibley A Thompson S van den Noort BY Weinshenker JS Wolinsky 2001 Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis Ann Neurol 50 121 127 10.1002/ana.1032 1:STN:280: DC%2BD38%2FitFOhug%3D%3D 11456302 (Pubitemid 32591472)
39. D Miller F Barkhof X Montalban A Thompson M Filippi 2005 Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis Lancet Neurol 4 281 288 10.1016/S1474-4422(05)70071-5 15847841 (Pubitemid 40545039)
40. EM Mowry M Pesic B Grimes SR Deen P Bacchetti E Waubant 2009 Clinical predictors of early second event in patients with clinically isolated syndrome J Neurol 256 1061 1066 10.1007/s00415-009-5063-0 19252775
41. JM Nielsen C Pohl CH Polman F Barkhof MS Freedman G Edan DH Miller L Bauer R Sandbrink L Kappos BM Uitdehaag 2009 MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome BMC Neurol 9 19 10.1186/1471-2377-9-19 19457248
42. KC O'Connor H Appel L Bregoli ME Call I Catz JA Chan NH Moore KG Warren SJ Wong DA Hafler KW Wucherpfennig 2005 Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein J Immunol 175 1974 1982 16034142
43. DT Okuda EM Mowry A Beheshtian E Waubant SE Baranzini DS Goodin SL Hauser D Pelletier 2009 Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome Neurology 72 800 805 10.1212/01.wnl. 0000335764.14513.1a 1:STN:280:DC%2BD1M7nsl2quw%3D%3D 19073949
44. SH Pelidou S Giannopoulos S Tzavidi G Lagos AP Kyritsis 2008 Multiple sclerosis presented as clinically isolated syndrome: the need for early diagnosis and treatment Ther Clin Risk Manag 4 627 630 18827858
45. C Polman L Kappos MS Freedman G Edan HP Hartung DH Miller X Montalban F Barkhof K Selmaj BM Uitdehaag S Dahms L Bauer C Pohl R Sandbrink 2008 Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b J Neurol 255 480 487 10.1007/s00415-007-0733-2 1:CAS:528: DC%2BD1cXosValtbg%3D 18004635
46. CH Polman SC Reingold G Edan M Filippi HP Hartung L Kappos FD Lublin LM Metz HF McFarland PW O'Connor M Sandberg-Wollheim AJ Thompson BG Weinshenker JS Wolinsky 2005 Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" Ann Neurol 58 840 846 10.1002/ana.20703 16283615 (Pubitemid 41746873)
47. CM Poser DW Paty L Scheinberg WI McDonald FA Davis GC Ebers KP Johnson WA Sibley DH Silberberg WW Tourtellotte 1983 New diagnostic criteria for multiple sclerosis: guidelines for research protocols Ann Neurol 13 227 231 10.1002/ana.410130302 1:STN:280:DyaL3s3gt1OgtQ%3D%3D 6847134 (Pubitemid 13158528)
48. GS Ramsaransing KJ De 2007 Predictive value of clinical characteristics for 'benign' multiple sclerosis Eur J Neurol 14 885 889 10.1111/j.1468-1331. 2007.01810.x 1:STN:280:DC%2BD2svksVegtg%3D%3D 17662009 (Pubitemid 47106771)
49. P Rieckmann 2006 [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)] Nervenarzt 77 1506 1518 10.1007/s00115-006- 2220-x 17136556 (Pubitemid 44950149)
50. AP Ross N Hackbarth C Rohl K Whitmyre 2008 Effective multiple sclerosis management through improved patient assessment J Neurosci Nurs 40 150 157 10.1097/01376517-200806000-00005 18578273
51. U Rot AH Ledinek SS Jazbec 2008 Clinical, magnetic resonance imaging, cerebrospinal fluid and electrophysiological characteristics of the earliest multiple sclerosis Clin Neurol Neurosurg 110 233 238 18093725
52. AL Sayao V Devonshire H Tremlett 2007 Longitudinal follow-up of "benign" multiple sclerosis at 20 years Neurology 68 496 500 10.1212/01.wnl.0000253185.03943.66 17296915
53. M Tintore 2007 Early MS treatment Int MS J 14 5 10 1:STN:280: DC%2BD2s3pvVWhsg%3D%3D 17509246
54. BD Trapp KA Nave 2008 Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31 247 269 10.1146/annurev.neuro.30.051606.094313 1:CAS:528:DC%2BD1cXpt12nsrY%3D 18558855
55. BD Trapp J Peterson RM Ransohoff R Rudick S Mork L Bo 1998 Axonal transection in the lesions of multiple sclerosis N Engl J Med 338 278 285 10.1056/NEJM199801293380502 1:STN:280:DyaK1c%2Fpt1SksA%3D%3D 9445407 (Pubitemid 28065253)
56. VK Tuohy RP Kinkel 2000 Epitope spreading: a mechanism for progression of autoimmune disease Arch Immunol Ther Exp (Warsz) 48 347 351 1:CAS:528:DC%2BD3MXoslGrug%3D%3D
57. BG Weinshenker 1995 The natural history of multiple sclerosis Neurol Clin 13 119 146 1:STN:280:DyaK2M3lslyqtA%3D%3D 7739500